Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
About the study
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- History of multiple myeloma with relapsed and refractory disease
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Must have measurable disease as determined by the central laboratory
EXCLUSION CRITERIA
Exclusion Criteria:
- Symptomatic central nervous system involvement of multiple myeloma
- Prior autologous stem cell transplant ≤ 3 months prior
- Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior
- History of concurrent second cancers requiring active, ongoing systemic treatment
Other protocol-defined inclusion/exclusion criteria apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Multiple Myeloma
Age (in years)
18+
Phase
Phase 1
Participants needed
250
Est. Completion Date
Aug 5, 2029
Treatment type
Interventional
Sponsor
Celgene
ClinicalTrials.gov identifier
NCT03486067
Study number
CC-93269-MM-001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?